512 related articles for article (PubMed ID: 17696759)
1. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
2. Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.
Baertschi S; Baur N; Lueders-Lefevre V; Voshol J; Keller H
J Biol Chem; 2014 Sep; 289(36):24995-5009. PubMed ID: 25012661
[TBL] [Abstract][Full Text] [Related]
3. Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats.
Jia HB; Ma JX; Ma XL; Yu JT; Feng R; Xu LY; Wang J; Xing D; Zhu SW; Wang Y
Osteoporos Int; 2014 Dec; 25(12):2743-54. PubMed ID: 25074352
[TBL] [Abstract][Full Text] [Related]
4. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
Li C; Wang W; Xie L; Luo X; Cao X; Wan M
Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
[TBL] [Abstract][Full Text] [Related]
6. N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.
Yang H; Dong J; Xiong W; Fang Z; Guan H; Li F
Ann N Y Acad Sci; 2016 Dec; 1385(1):41-52. PubMed ID: 27723935
[TBL] [Abstract][Full Text] [Related]
7. Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D
St John HC; Hansen SJ; Pike JW
J Steroid Biochem Mol Biol; 2016 Nov; 164():277-280. PubMed ID: 26361013
[TBL] [Abstract][Full Text] [Related]
8. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion.
Wijenayaka AR; Yang D; Prideaux M; Ito N; Kogawa M; Anderson PH; Morris HA; Solomon LB; Loots GG; Findlay DM; Atkins GJ
Mol Cell Endocrinol; 2015 Sep; 413():157-67. PubMed ID: 26112182
[TBL] [Abstract][Full Text] [Related]
9. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
[TBL] [Abstract][Full Text] [Related]
10. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
11. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
[TBL] [Abstract][Full Text] [Related]
12. Mef2c deletion in osteocytes results in increased bone mass.
Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
[TBL] [Abstract][Full Text] [Related]
13. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
14. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
Loots GG; Kneissel M; Keller H; Baptist M; Chang J; Collette NM; Ovcharenko D; Plajzer-Frick I; Rubin EM
Genome Res; 2005 Jul; 15(7):928-35. PubMed ID: 15965026
[TBL] [Abstract][Full Text] [Related]
15. Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis.
Ye W; Wang Y; Mei B; Hou S; Liu X; Wu G; Qin L; Zhao K; Huang Q
Bone; 2018 Mar; 108():132-144. PubMed ID: 29307778
[TBL] [Abstract][Full Text] [Related]
16. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.
Bonnet N; Conway SJ; Ferrari SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15048-53. PubMed ID: 22927401
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
Delgado-Calle J; Sañudo C; Bolado A; Fernández AF; Arozamena J; Pascual-Carra MA; Rodriguez-Rey JC; Fraga MF; Bonewald L; Riancho JA
J Bone Miner Res; 2012 Apr; 27(4):926-37. PubMed ID: 22162201
[TBL] [Abstract][Full Text] [Related]
18. Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D
Wijenayaka AR; Prideaux M; Yang D; Morris HA; Findlay DM; Anderson PH; Atkins GJ
J Steroid Biochem Mol Biol; 2016 Nov; 164():369-373. PubMed ID: 26690786
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element.
Yu L; van der Valk M; Cao J; Han CY; Juan T; Bass MB; Deshpande C; Damore MA; Stanton R; Babij P
Bone; 2011 Dec; 49(6):1131-40. PubMed ID: 21890009
[TBL] [Abstract][Full Text] [Related]
20. MEF2C Interacts With c-FOS in PTH-Stimulated Mmp13 Gene Expression in Osteoblastic Cells.
Nakatani T; Partridge NC
Endocrinology; 2017 Nov; 158(11):3778-3791. PubMed ID: 28973134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
